Saturday 17 October 2026
Export CELZ’s income statement to Excel — free account
Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.
0.74
0.08
−9.76%
Follow CELZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
— | — | 274.72 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (2.41) | — | |
P/B ratio |
— | — | 0.62 | — | |
Price to Tangible BV |
— | — | 0.66 | — | |
EV/Sales |
— | — | (142.33) | — | |
EV/EBITDA |
— | — | 0.40 | — | |
EV/Operating CF |
— | — | 0.41 | — | |
EV/FCF |
— | — | 0.22 | — | |
Quick Ratio |
12.65 | 19.01 | 25.30 | 20.56 | |
Current Ratio |
12.91 | 19.70 | 25.97 | 20.70 | |
Net Debt/EBITDA |
5.73 | 4.08 | 3.76 | 4.33 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.97 | 0.94 | 1.03 | 0.95 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
30.69 | — | — | 34.31 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 18,336.67% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 45,560.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.06 | 0.05 | 0.07 | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Graham Net Nets |
— | — | 1.52 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (132.14%) | — | |
Free Cash Flow Yield |
— | — | (239.34%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.40) | (0.36) | (0.81) | (0.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | (0.36) | (0.81) | (0.45) | |
Cash per Share |
2.39 | 1.58 | 3.03 | 2.08 | |
Shareholders Equity per Share |
2.34 | 1.66 | 3.16 | 2.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.34 | 1.66 | 3.16 | 2.17 | |
Free Cash Flow |
(1.47) | (1.32) | (1.94) | (1.17) | |
Working Capital |
8.32 | 5.75 | 7.11 | 5.15 | |
Net Current Asset Value |
8.32 | 5.75 | 7.11 | 5.15 | |
EV/EBIT |
— | — | 0.39 | — | |
Capex to Sales |
— | — | 0.00 | — | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Payables |
0.47 | 0.28 | 0.27 | 0.26 | |
Average Inventory |
— | — | — | 0.00 | |
Average Assets |
8.24 | 7.39 | 7.24 | 6.37 | |
Average Common Equity |
7.75 | 7.10 | 6.93 | 6.07 |
Columns are period end dates